{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:51:51Z","timestamp":1782913911713,"version":"3.54.5"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cure Parkinson\u2019s","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"NIHR Oxford Health Clinical Research Facility","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["16\/167\/19"],"award-info":[{"award-number":["16\/167\/19"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson\u2019s UK","doi-asserted-by":"publisher","award":["PRO-25-395 001"],"award-info":[{"award-number":["PRO-25-395 001"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merz and Ipsen","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,6,6]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Digital health technologies offer high-frequency, objective measures for Parkinson\u2019s disease (PD) yet individual stratification is lacking. This study aimed to identify and predict fast versus slow PD motor progressors by integrating longitudinal clinical evaluation with smartphone motor testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this 96-week subgroup analysis of participants in the Exenatide-PD3 trial, motor progression was measured using Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale Part III OFF scores and smartphone testing (baseline, weeks 24, 48, 72, 96). Fast versus slow progressors were identified using data-driven subtyping; linear mixed-effects models assessed longitudinal OFF scores. Baseline clinical and digital features (in-clinic and at-home) were used to predict 96-week motor progression. Model performance was quantified by the area under the receiver operating curve (AUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data-driven clustering identified 26.5% (26\/98) as fast progressors, with higher baseline OFF scores (+18.16, 95%\u2009CI 13.70 to 22.62; adjusted p&lt;0.001) and greater 96-week progression (+8.17, 95%\u2009CI 2.75 to 13.60; adjusted p=0.019), undetected by prespecified approaches. Baseline prediction models combining smartphone features, alone or with clinical scores, consistently outperformed the clinical model alone (best AUC=0.78\u2009vs 0.53). Translational value of smartphone assessments was strengthened by high user acceptability (&gt;96% support future in-clinic use) and predictive value in a deployment scenario (AUC 0.80, 95%\u2009CI 0.79 to 0.82).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Data-driven clustering identified one in four early-to-mid stage PD patients as fast motor progressors. Integrating smartphone-derived features with clinical scores improved baseline motor prediction. High user acceptability supports this approach for individual-level PD stratification, addressing heterogeneity in motor progression that may obscure treatment trial effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2026-001740","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:40:50Z","timestamp":1782913250000},"page":"e001740","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying and predicting fast versus slow Parkinson\u2019s disease motor progressors using clinical and digital data"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0151-6397","authenticated-orcid":false,"given":"Timothee","family":"Aubourg","sequence":"first","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina M","family":"Gunter","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lo","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Department of Clinical Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Welch","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Groenewald","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-2801","authenticated-orcid":false,"given":"Johannes C","family":"Klein","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Razzaque","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Van Hillegondsberg","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Luca","family":"Ratti","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Nastasa","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Auld","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Mccomish","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"King","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashfia","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirosen","family":"Vijiaratnam","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Girges","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Patrick","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma","family":"Inches","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille B","family":"Carroll","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth, Plymouth, UK"},{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Foltynie","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Arora","sequence":"additional","affiliation":[{"name":"Said Business School, University of Oxford, Oxford, UK"},{"name":"Somerville College, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-5841","authenticated-orcid":false,"given":"Michele T.","family":"Hu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"},{"name":"Oxford Parkinson\u2019s Disease Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026070106251182000_8.2.e001740.1","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"The Lancet"},{"key":"2026070106251182000_8.2.e001740.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"2026070106251182000_8.2.e001740.3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1212\/WNL.0000000000004078","article-title":"Baseline motor findings and Parkinson disease prognostic subtypes","volume":"89","author":"Rajput","year":"2017","journal-title":"Neurology"},{"key":"2026070106251182000_8.2.e001740.4","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.11.1724"},{"key":"2026070106251182000_8.2.e001740.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.131045"},{"key":"2026070106251182000_8.2.e001740.6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000477383","article-title":"The First Frontier: Digital Biomarkers for Neurodegenerative Disorders","volume":"1","author":"Dorsey","year":"2017","journal-title":"Digit Biomark"},{"key":"2026070106251182000_8.2.e001740.7","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20640"},{"key":"2026070106251182000_8.2.e001740.8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.parkreldis.2015.02.026","article-title":"Detecting and monitoring the symptoms of Parkinson\u2019s disease using smartphones: A pilot study","volume":"21","author":"Arora","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"2026070106251182000_8.2.e001740.9","doi-asserted-by":"crossref","unstructured":"Kinan M , Francis C , Siddharth A , et al . Neu health: smartphone-based remote digital monitoring for parkinson\u2019s disease and dementia. Neu health: smartphone-based remote digital monitoring for Parkinson\u2019s disease and dementia, BMJ Publishing Group Ltd; November 2024:1\u2013A13. doi:10.1136\/jnnp-2024-ABN.43","DOI":"10.1136\/jnnp-2024-ABN.43"},{"key":"2026070106251182000_8.2.e001740.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-024-00721-2","article-title":"Using a smartwatch and smartphone to assess early Parkinson\u2019s disease in the WATCH-PD study over 12 months","volume":"10","author":"Adams","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"2026070106251182000_8.2.e001740.11","doi-asserted-by":"crossref","DOI":"10.1007\/s10916-021-01760-5","article-title":"Gait and Balance Assessments using Smartphone Applications in Parkinson\u2019s Disease: A Systematic Review","volume":"45","author":"Abou","year":"2021","journal-title":"J Med Syst"},{"key":"2026070106251182000_8.2.e001740.12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamaneurol.2018.0809","article-title":"Using Smartphones and Machine Learning to Quantify Parkinson Disease Severity: The Mobile Parkinson Disease Score","volume":"75","author":"Zhan","year":"2018","journal-title":"JAMA Neurol"},{"key":"2026070106251182000_8.2.e001740.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006366"},{"key":"2026070106251182000_8.2.e001740.14","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/acn3.50853","article-title":"Predicting motor, cognitive & functional impairment in Parkinson\u2019s","volume":"6","author":"Lo","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"2026070106251182000_8.2.e001740.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-025-01572-8","article-title":"Exploratory digital outcome measures of motor sign progression in Parkinson\u2019s disease patients treated with prasinezumab","volume":"8","author":"Taylor","year":"2025","journal-title":"NPJ Digit Med"},{"key":"2026070106251182000_8.2.e001740.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15874-4","article-title":"Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson\u2019s disease","volume":"12","author":"Lipsmeier","year":"2022","journal-title":"Sci Rep"},{"key":"2026070106251182000_8.2.e001740.17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(23)00376-9","article-title":"Digital mobility measures to predict Parkinson\u2019s disease","volume":"22","author":"Mirelman","year":"2023","journal-title":"Lancet Neurol"},{"key":"2026070106251182000_8.2.e001740.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-021-00248-w","article-title":"A real-world study of wearable sensors in Parkinson\u2019s disease","volume":"7","author":"Adams","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"key":"2026070106251182000_8.2.e001740.19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"The Lancet"},{"key":"2026070106251182000_8.2.e001740.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02886-y"},{"key":"2026070106251182000_8.2.e001740.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22360"},{"key":"2026070106251182000_8.2.e001740.22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JPD-140523","article-title":"Parkinson\u2019s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort","volume":"5","author":"Lawton","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"2026070106251182000_8.2.e001740.23","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00964-w"},{"key":"2026070106251182000_8.2.e001740.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040527","article-title":"Azathioprine immunosuppression and disease modification in Parkinson\u2019s disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol","volume":"10","author":"Greenland","year":"2020","journal-title":"BMJ Open"},{"key":"2026070106251182000_8.2.e001740.25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2011.240366"},{"key":"2026070106251182000_8.2.e001740.26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41531-022-00287-x","article-title":"The emerging postural instability phenotype in idiopathic Parkinson disease","volume":"8","author":"Skidmore","year":"2022","journal-title":"npj Parkinsons Dis"},{"key":"2026070106251182000_8.2.e001740.27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/WNL.0000000000002437","article-title":"Development and external validation of a prognostic model in newly diagnosed Parkinson disease","volume":"86","author":"Velseboer","year":"2016","journal-title":"Neurology"},{"key":"2026070106251182000_8.2.e001740.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002461"},{"key":"2026070106251182000_8.2.e001740.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-025-02148-2","article-title":"Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson\u2019s disease","volume":"8","author":"Gunter","year":"2025","journal-title":"NPJ Digit Med"},{"key":"2026070106251182000_8.2.e001740.30","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327376"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:40:59Z","timestamp":1782913259000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjno-2026-001740"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001740","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}